Sam Chun Dang Pharm shares fell in early trading on the 16th after news that the Korea Exchange (KRX) had referred the company to the KOSDAQ market disclosure committee for review over a disclosure violation.

Jeon In-seok, CEO of Sam Chun Dang Pharm, answers reporters' questions at the SCD 2026 press conference at the company's headquarters in Seocho-gu, Seoul, on the afternoon of the 6th. /Courtesy of News1

As of 9:32 a.m., Sam Chun Dang Pharm was trading on the KOSDAQ at 527,000 won, down 5.05% (28,000 won) from the previous session.

Before the market opened, the exchange said a disclosure committee composed of external experts would review Sam Chun Dang Pharm, taking into account the motive and materiality of the disclosure violation.

Earlier, on the 31st of last month, the exchange issued a preliminary notice designating Sam Chun Dang Pharm as an unfaithful disclosure entity, citing "failure to implement fair disclosure of outlooks or forecasts on business performance." The exchange will decide whether to designate Sam Chun Dang Pharm as an unfaithful disclosure entity by the 23rd.

※ This article has been translated by AI. Share your feedback here.